P. Ravva

发表

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization

L. Gibiansky, K. Patel, Patrick F. Smith, 2020, British journal of clinical pharmacology.

Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.

R. Niaura, M. Gastonguay, P. Ravva, 2015, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Justin C. Earp, P. Bonate, M. Karlsson, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY

P. Villiger, P. Ravva, A. Sostelly, 2019, Oral Presentations.

Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults

M. Karlsson, L. Friberg, Ping Liu, 2012, Antimicrobial Agents and Chemotherapy.

Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants

L. Gibiansky, N. Parrott, S. Sturm, 2020, Clinical pharmacology and therapeutics.

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

R. Obach, A. Burstein, H. Rollema, 2010, Clinical pharmacokinetics.

Quantitative Assessment of Exposure–Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation

J. French, T. Tensfeldt, M. Gastonguay, 2010, Clinical pharmacology and therapeutics.

Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

P. Ravva, H. Faessel, K. Williams, 2009, Clinical therapeutics.

Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy

Timothy D. Knab, L. Gibiansky, J. Hernández-Sánchez, 2021, British journal of clinical pharmacology.

Population pharmacokinetic analysis of varenicline in adult smokers.

T. Tensfeldt, M. Gastonguay, P. Ravva, 2009, British journal of clinical pharmacology.

Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Justin C. Earp, P. Bonate, M. Karlsson, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel

C. Adessi, F. Mercier, Chao-bin Xu, 2018, Cancer Chemotherapy and Pharmacology.

Missing Data in Model‐Based Pharmacometric Applications: Points to Consider

Daniel F Heitjan, Marc R Gastonguay, Jae Eun Ahn, 2010, Journal of clinical pharmacology.

A linearization approach for the model‐based analysis of combined aggregate and individual patient data

Mats O Karlsson, Patanjali Ravva, J. French, 2014, Statistics in medicine.